Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 47-55
Closed Access | Times Cited: 61
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 21
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, et al.
JAMA Psychiatry (2025)
Closed Access | Times Cited: 2
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 36
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Guy Pelletier, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 617-617
Open Access | Times Cited: 15
POTENTIAL ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS IN SUBSTANCE USE DISORDER: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS
Silvia Martinelli, Alessandro Mazzotta, Mattia Longaroni, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112424-112424
Open Access | Times Cited: 11
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 10
Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2025), pp. 101612-101612
Closed Access | Times Cited: 1
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking
R. Merkel, Nicole S. Hernandez, Vanessa Weir, et al.
Science Advances (2025) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Wilfredo López-Ojeda, Robin A. Hurley
Journal of Neuropsychiatry (2024) Vol. 36, Iss. 2, pp. A4-86
Closed Access | Times Cited: 6
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Hubertus Himmerich, Susan L. McElroy
Journal of Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 6
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Rae J. Herman, Heath D. Schmidt
Physiology & Behavior (2024) Vol. 281, pp. 114565-114565
Open Access | Times Cited: 6
Novel medications for problematic alcohol use
Markus Heilig, Katie Witkiewitz, Lara A. Ray, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 11
Open Access | Times Cited: 6
Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review
Mohsan Subhani, Ashwin Dhanda, James A. King, et al.
EClinicalMedicine (2024), pp. 102920-102920
Open Access | Times Cited: 6
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Daisuke Hayashi Neto, Caitlyn G. Edwards, Jennifer A. Emond, et al.
Nutrients (2023) Vol. 15, Iss. 22, pp. 4809-4809
Open Access | Times Cited: 12
Alcohol and the dopamine system
Bo Söderpalm, Mia Ericson
International review of neurobiology (2024), pp. 21-73
Closed Access | Times Cited: 4
An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking
R. Merkel, Nicole S. Hernandez, Vanessa Weir, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder
Elisabet Jerlhag
Endocrinology (2025) Vol. 166, Iss. 4
Open Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder
Sree Sudha Tanguturi Yella, Krishna Sasanka Kota Sesha Brahma Sree, Sumit Kumar Mahato
Journal of Clinical Psychopharmacology (2025)
Closed Access
Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder
Tingting Liu, Fuqiang Shi, Zhihua Guo, et al.
Pharmacopsychiatry (2025)
Closed Access
Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Matthew L. Basa, S. Danielle, David Mitchell, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 3
Open Access | Times Cited: 3
Contribution of Visceral Systems to the Development of Substance Use Disorders: Translational Aspects of Interaction between Central and Peripheral Mechanisms
Д. И. Перегуд, N. V. Gulyaeva
Biochemistry (Moscow) (2024) Vol. 89, Iss. 11, pp. 1868-1888
Open Access | Times Cited: 2
Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
Stefania Chiappini, Rachel Vickers‐Smith, Duccio Papanti, et al.
(2023)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top